ANTIMICROBIAL RESISTANCE SOLUTIONS

WITH DR. JOHN H. REX

Latest Newsletters

Latest Government Action

Can you help?

AMR Fireside Chats
1/19 videos
1
Episode 18 w/Robin Hiley- Fireside Chat
Episode 18 w/Robin Hiley- Fireside Chat
19:48
2
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
3
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
4
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
5
Episode 14 w/ Lynn Silver - AMR Fireside Chat
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
6
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
7
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
8
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
9
Episode 10 w/ Anna Govett - AMR Fireside Chat
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
10
Episode 9 w/ Fatema Rafiqi, PhD -  AMR Fireside Chat
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
11
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
12
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
13
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
14
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
15
Episode 5 w/ Christine Årdal - AMR Fireside Chat
Episode 5 w/ Christine Årdal - AMR Fireside Chat
43:44
16
Episode 4 w/ Peter Beyer - AMR Fireside Chat
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
17
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
18
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
19
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
R&D Insight

Developing systemic & inhaled antibiotics for lung infections

Dear All: I missed it personally, but by all reports the session on 3 June 2017 at ASM Microbe entitled “Development of New Drugs and ...
Read More →
R&D Insight

Scary, Scarier, Scariest (Part 2): What can YOU do about it?

Long note alert— apologies! Get a cup of coffee and settle in… Dear All: My 22 Apr 2019 note entitled Scary, Scarier, Scariest: Achaogen / FT ...
Read More →
Government Action

The 6 meanings of “Lack of Access” (UNSLAP)

Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year ...
Read More →
R&D Insight

Non-traditional antibiotics: A pipeline review and an analysis of key development challenges

Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress ...
Read More →
Government Action

Lancet: 10-20-30 targets to address AMR by 2030

Dear All (wonkish alert … but definitely worth the effort! Refill your coffee!),Ramanan Laxminarayan and about 40 colleagues from around the world have just published in ...
Read More →
Push/Pull

Push! Pull! Push! Pull! / Highlights from Davos 2018

Dear All: Three important documents were released at / during / around the World Economic Forum meeting that occurred this week in Davos. First and foremost, ...
Read More →
R&D Insight

Developing antibiotics for children: There are no easy answers

Aside: If you’ve enjoyed the prior discussions of movies to inspire antibiotic R&D and very apropos given the theme of today’s newsletter, please check out the ...
Read More →
R&D Insight

Lessons in Discovery from Lynn Silver + Pro-con on alternatives to antibiotics

Dear All: “Good decisions come from experience, and experience comes from bad decisions … and paying attention.” You’ve probably heard the first part of that ...
Read More →
R&D Insight

De-risking vaccine development: Insights spanning decades of experience

Dear All (with thanks to Vega Masignani for co-authoring this newsletter), While the work needed to create new antibacterial agents is the primary topic of ...
Read More →
Push/Pull

New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020

Dear All (wonkish alert: coffee up, settle in, and read the reports!), As you will recall, WHO’s most current pipeline review found that globally we ...
Read More →
R&D Insight

DTR Gram-negative infections: Are new antibiotics making a difference?

Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be a long, wonkish, but VERY ...
Read More →
FDA

FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)

Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about ...
Read More →
Scroll to Top